AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Decrease in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totaling 137,078 shares, a decline of 54.8% from the April 30th total of 303,165 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average trading volume of 1,558,811 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Zacks Research cut AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Institutional Trading of AIM ImmunoTech

Institutional investors have recently added to or reduced their stakes in the stock. DRW Securities LLC boosted its holdings in AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock valued at $79,000 after acquiring an additional 26,254 shares during the last quarter. Sabby Management LLC bought a new stake in AIM ImmunoTech in the third quarter valued at approximately $79,000. Finally, Corient Private Wealth LLC bought a new stake in AIM ImmunoTech in the second quarter valued at approximately $87,000. 12.02% of the stock is currently owned by institutional investors.

AIM ImmunoTech Trading Down 6.5%

AIM stock traded down $0.03 during trading on Friday, hitting $0.41. The company had a trading volume of 11,966,202 shares, compared to its average volume of 55,690,520. The business has a 50-day moving average of $0.51 and a 200-day moving average of $0.96. AIM ImmunoTech has a one year low of $0.21 and a one year high of $20.35. The stock has a market cap of $5.94 million, a PE ratio of -0.06 and a beta of 1.24. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 0.10.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its earnings results on Friday, May 15th. The company reported ($0.69) EPS for the quarter. The company had revenue of $0.02 million during the quarter. Research analysts predict that AIM ImmunoTech will post -1.47 earnings per share for the current fiscal year.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.